EDGAR·FLOW

AETHLON MEDICAL INC — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 92/100
What the filing says
Aethlon Medical (AEMD, $5.7M market cap) is combining with North Immunology via business combination where North becomes a wholly owned subsidiary of AEMD. Concurrent private placement of $180M (inclusive of $34M convertible note) will be raised. Post-closing capitalization: AEMD 4.75%, North 43.17%, PIPE investors 52.08% (71.2M total shares). North's lead asset NOR-101 is a half-life extended anti-IL-13 × IL-18 bispecific antibody targeting atopic dermatitis, with Phase 1a planned Q1 2027.
Why this rating

Transformational M&A for $5.7M company: massive capital infusion ($180M), new clinical-stage biotech platform, and 43% post-deal ownership. Existential recapitalization.

Tradability signal
NO TRADE

No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.46% over 4 hrs, n=30). (Filing arrived outside market hours — evaluated at the next open with a live quote.)

Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.

Price action (we called it positive)
before filing · preread
$5.01 ▲ 0.00%
at our read · unknown
$5.01
+10 min · unknown
$5.01 ▲ 0.00%
+30 min · unknown
$5.05 ▲ 0.80%
+1 hr · unknown
$5.02 ▲ 0.28%
+4 hrs · unknown
$5.00 ▼ 0.30%

The stock had already moved +0.00% between hitting EDGAR and our read finishing — deltas above are measured from our read.

Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →

View original filing on SEC.gov ↗ AEMD · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.